"Hua Guan Biological" completes B billion yuan in Series B financing

Irai News on September 27th, Beijing Huaguan Biotechnology Co., Ltd., a pharmaceutical and intermediate producer, announced the completion of more than 100 million yuan in Series B financing. Ling and Shengmei Jiale followed.

Public information shows that Beijing Huaguan Biotechnology Co., Ltd. was established in 2016. In February 2018, it obtained an angel round investment from the Tsinghua University Hutang International Health Fund, and then completed the Pre-A round of PRE-A in February 2020. Beijing Huaguan Biotechnology Co., Ltd. is a national high -tech enterprise. Huaguan Bio has a 1,800 square meter standard laboratory in Yongfeng Base, Haidian District, Beijing. It has advanced experimental equipment that supports preclinical pharmacy research.

All the core teams represented by Dr. Chen Jian have rich domestic and international industrialization research and development experiences of innovative drugs/imitation drugs, and are committed to creating a multi -wheel drive pharmaceutical industrialization innovation platform. The company provides integrated pharmaceutical research and development services for domestic and foreign pharmaceutical companies, covering the fields of original innovative drugs, innovative preparations, generic drugs, and rare diseases.

According to the smart buds of innovation forces, there are currently eight public applications for Bi Guan Bio, all of which are invention patents, which are mainly concentrated in related fields such as intermediates and phosphates.

In addition, the company has established a complete R & D quality management system, which meets the highest requirements of the State Drug Administration and FDA on data integrity and traceability. Based on the positioning of the pharmacy research and development platform, the integrated upstream and downstream institutions and enterprises of Huaguan biology have continuously innovated in the combination of industry -university -research, transformation of scientific research results, innovative drug research and development, rare diseased drugs, and quality management of the entire life cycle of drugs.

- END -